- Conditions
- Healthy Male and Female Subjects
- Interventions
- Dapagliflozin, Metformin, Dapagliflozin + Metformin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Hamilton, New Jersey
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Healthy
- Interventions
- Escitalopram on days -7 to day 14; Aripiprazole dosed starting Day 1 to day 14: 3 days at 10 mg, 4 days at 15 mg and 7 days at 20 mg
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- Psychosocial Stress
- Interventions
- Therapy dog visitation (TDV), non-TDV control
- Behavioral
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 7 Years to 17 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- COVID-19
- Interventions
- ALG-097558, Dabigatran, Itraconazole, Placebo
- Drug · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Healthy Volunteer
- Interventions
- ABBV-903, Midazolam
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Grayslake, Illinois
- Conditions
- Postmenopause
- Interventions
- Premarin
- Drug
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 35 Years to 70 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Healthy
- Interventions
- Midazolam, SSP-004184SS
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Venous Thromboembolism, Pharmacokinetics, Healthy
- Interventions
- Apixaban alone, Cyclosporine, Tacrolimus, Apixaban
- Drug
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Acute Respiratory Distress Syndrome (ARDS)
- Interventions
- Not listed
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 367 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Healthy, PK Drug-drug Interaction Study
- Interventions
- Hydrocodone Bitartrate, Hydrocodone Bitartrate + Doxapram Hydrochloride
- Drug
- Lead sponsor
- Quivive Pharma, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Secaucus, New Jersey
- Conditions
- HIV Infections, Tuberculosis
- Interventions
- Nelfinavir, Rifabutin
- Drug
- Lead sponsor
- Centers for Disease Control and Prevention
- Federal
- Eligibility
- 0 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2002
- U.S. locations
- 20
- States / cities
- Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 15 more
- Conditions
- Physical Inactivity, Dietary Protein
- Interventions
- normal protein diet, high protein intake
- Behavioral
- Lead sponsor
- University of Missouri-Columbia
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Columbia, Missouri
- Conditions
- Body Composition, Energy Balance, Metabolism
- Interventions
- Not listed
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 3 Years to 7 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Type2 Diabetes Mellitus
- Interventions
- Bexagliflozin, Metformin, Glimepiride, Sitagliptin
- Drug
- Lead sponsor
- Theracos
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Evansville, Indiana
- Conditions
- Cochlear Implant Users
- Interventions
- Experiment 1: Syntactic and Semantic Context, Experiment 2: False Hearing and Context Overuse, Experiment 3: Two-Sentence Problem, Experiment 4: Cascading Effects on Discourse Comprehension, Experiment 5: Self-Paced Discourse Comprehension, Experiment 6: Clinical Application
- Behavioral
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 460 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2030
- U.S. locations
- 2
- States / cities
- Waltham, Massachusetts • New York, New York
- Conditions
- Language Development Disorders, Autism Spectrum Disorder
- Interventions
- Enhanced Milieu Teaching, no intervention comparison group
- Behavioral · Other
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 30 Months and older
- Enrollment
- 156 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Healthy Volunteers
- Interventions
- ASP8062, Alcohol, ASP8062 Placebo, Alcohol Placebo
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 21 Years to 55 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Pharmacokinetics
- Interventions
- Regorafenib (BAY73-4506); Regorafenib (BAY73-4506) plus ketoconazole
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 45 Years · Male only
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Brighton, Massachusetts
- Conditions
- Healthy Adult Participants
- Interventions
- Not listed
- Lead sponsor
- Ecotera Health LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 51
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 48 more
- Conditions
- Healthy
- Interventions
- Test formulation administered with water, Test formulation administered with 20% ethanol, Test formulation administered with 40% ethanol
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 21 Years to 55 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Atherosclerosis, Cardiovascular Disease
- Interventions
- GW856553
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Drug-Interactions
- Interventions
- ecopipam HCl ~2mg/kg/day, Cohort 1 Probe Cocktail, Cohort 2 Probe Cocktail, Cohort 3 Probe Cocktail
- Drug · Combination Product
- Lead sponsor
- Emalex Biosciences Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Healthy Volunteers
- Interventions
- Tasimelteon, Rosiglitazone, Midazolam
- Drug
- Lead sponsor
- Vanda Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Springfield, Missouri
- Conditions
- Major Depressive Disorder
- Interventions
- LY2216684, Placebo-matching LY2216684, Placebo-matching alcoholic beverage, Alcoholic beverage
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Evansville, Indiana